In vivo antiarrhythmic profile of AP-792 assessed in different canine arrhythmia models.

Abstract

The antiarrhythmic effects of a novel antiarrhythmic drug AP-792, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-[4-cyclohexylbutyl]piperidine hydrochloride, were analyzed using the epinephrine-, digitalis- and two-stage coronary ligation-induced canine ventricular arrhythmia models. Intravenous administration of AP-792 (0.3 or 1.0 mg/kg) effectively suppressed each of the ventricular arrhythmias, an action that resembles that of a typical cardioselective Ca2+ channel blocker, AH-1058. The antiarrhythmic action of AP-792 was slow in onset and longer-lasting than those in our previous studies using more than 50 antiarrhythmic drugs, including Na+ and Ca2+ channel blockers. These results suggest that AP-792 can become a unique long-acting antiarrhythmic drug.

• Authors: A Takahara, A Hirasawa, H Dohmoto, M Shoji, R Yoshimoto, A Sugiyama, K Hashimoto
• Journal: Japanese journal of pharmacology (Jpn J Pharmacol) Vol. 87 Issue 1 Pg. 21-6 (Sep 2001) ISSN: 0021-5198 [Print] Japan
• PMID: 11676194 (Publication Type: Comparative Study, Journal Article)

Chemical References

• AP792
• Anti-Arrhythmia Agents
• Calcium Channel Blockers
• Piperidines
• Sodium Channel Blockers
• Epinephrine

Topics

• Animals
• Anti-Arrhythmia Agents (chemistry, pharmacology)
• Arrhythmias, Cardiac (chemically induced, physiopathology)
• Calcium Channel Blockers (pharmacology)
• Digitalis (adverse effects)
• Disease Models, Animal
• Dogs
• Electrocardiography (drug effects)
• Epinephrine (adverse effects)
• Heart Ventricles (drug effects)
• Injections, Intravenous
• Ligation (adverse effects)
• Piperidines (chemistry, pharmacology)
• Sodium Channel Blockers (pharmacology)